Emerging and Repurposed Immune System Modulators for Alzheimer’s Disease
- 1Department of Pharmacology and Neuroscience, Texas Tech University Health Sciences Center, Lubbock, TX, USA
- 2Department of Neurology, Barrow Neurological Institute, Phoenix, AZ, USA
- 3School of Medicine, Creighton University, Phoenix, AZ, USA
Abstract
Alzheimer’s disease (AD) remains an incurable neurodegenerative condition to date. Pathologically, the hallmarks of AD are (i) extracellular senile plaques mainly composed of amyloid beta peptides (Aβ), (ii) intracellular neurofibrillary tangles comprised of abnormally folded and hyperphosphorylated tau proteins, and (iii) neuroinflammation. In the past two decades, the investigation of these brain pathologies has led to the identification of novel diagnostic biomarkers and putative therapeutic targets, ultimately resulting in the first two commercial disease-modifying anti-Aβ immunotherapies. More recently, modulation of the overactivated central immune system has emerged as a unique putative approach to slow down the progression of AD. In the present narrative review, we summarize the main findings on modulators of inflammation tested in Phase 2 and 3 trials in AD patients. After a deep literature review, we ended up selecting 19 agents spanning immune primers, monoclonal antibodies, recombinant proteins, synthetic peptides, immunomodulatory drugs, ion channel blockers, tyrosine kinase inhibitors, senolytics, antivirals, and herbal formulations. For each agent, we briefly explain the preclinical findings that led to translation into clinical trials and provide details about each trial design, and, when available, the main findings from the trials. Overall, it appears that Aβ and abnormal tau activate both the innate and adaptive immune systems, which in turn galvanize the production of Aβ and abnormal tau, thereby forming a viscous cycle that inflates AD neuropathology and is difficult to interrupt. Based on the successes and failures of the 19 agents reported here, we postulate that immune system modulators with the strongest potential for AD treatment are those displaying pleiotropic actions on both innate and adaptive immune responses rather than those exhibiting very targeted mechanisms. We conclude that modulators of inflammation need to be studied further, both as stand-alone AD therapies and in combination with anti-amyloid and anti-tau approaches.
Related
- Structure-Based Discovery of GTP-Enhanced Rab10 Modulators and Their Effects on Alzheimer Disease-Relevant Cellular Phenotypes
- Clockophagy in Alzheimer’s Disease: An Emerging Hypothesis Linking Circadian Dysfunction to Ferroptotic Vulnerability
- Multi-Cohort Transcriptomic Integration Identifies Overlapping Immune and Antigen-Presentation Features in Alzheimer’s Disease and Hashimoto’s Thyroiditis
- Cross-Dataset Reanalysis of Mouse Alzheimer Disease Single-Cell RNA-Sequencing Data Reveals a Reproducible Innate Immune Activation Signature
- Remodeling of the brain immune microenvironment in Alzheimer’s disease: interactions among microglia, astrocytes, complement, and the neurovascular unit
BibTeX
@article{decourt2026emerging,
title = {{Emerging and Repurposed Immune System Modulators for Alzheimer’s Disease}},
author = {Boris Decourt and Katia Azarfar and Ellie Marie Reyna and Jessica Marianne Kennedy and Marwan N Sabbagh},
journal = {Drug Design, Development and Therapy},
year = {2026},
month = oct,
doi = {10.2147/dddt.s559284},
url = {https://doi.org/10.2147/dddt.s559284},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Emerging and Repurposed Immune System Modulators for Alzheimer’s Disease
AU - Boris Decourt
AU - Katia Azarfar
AU - Ellie Marie Reyna
AU - Jessica Marianne Kennedy
AU - Marwan N Sabbagh
PY - 2026
DA - 2026/10/30
JO - Drug Design, Development and Therapy
DO - 10.2147/dddt.s559284
UR - https://doi.org/10.2147/dddt.s559284
AB - Alzheimer’s disease (AD) remains an incurable neurodegenerative condition to date. Pathologically, the hallmarks of AD are (i) extracellular senile plaques mainly composed of amyloid beta peptides (Aβ), (ii) intracellular neurofibrillary tangles comprised of abnormally folded and hyperphosphorylated tau proteins, and (iii) neuroinflammation. In the past two decades, the investigation of these brain pathologies has led to the identification of novel diagnostic biomarkers and putative therapeutic targets, ultimately resulting in the first two commercial disease-modifying anti-Aβ immunotherapies. More recently, modulation of the overactivated central immune system has emerged as a unique putative approach to slow down the progression of AD. In the present narrative review, we summarize the main findings on modulators of inflammation tested in Phase 2 and 3 trials in AD patients. After a deep literature review, we ended up selecting 19 agents spanning immune primers, monoclonal antibodies, recombinant proteins, synthetic peptides, immunomodulatory drugs, ion channel blockers, tyrosine kinase inhibitors, senolytics, antivirals, and herbal formulations. For each agent, we briefly explain the preclinical findings that led to translation into clinical trials and provide details about each trial design, and, when available, the main findings from the trials. Overall, it appears that Aβ and abnormal tau activate both the innate and adaptive immune systems, which in turn galvanize the production of Aβ and abnormal tau, thereby forming a viscous cycle that inflates AD neuropathology and is difficult to interrupt. Based on the successes and failures of the 19 agents reported here, we postulate that immune system modulators with the strongest potential for AD treatment are those displaying pleiotropic actions on both innate and adaptive immune responses rather than those exhibiting very targeted mechanisms. We conclude that modulators of inflammation need to be studied further, both as stand-alone AD therapies and in combination with anti-amyloid and anti-tau approaches.
SN - 1177-8881
ER -